Difference between revisions of "Autoimmune cytopenia"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "'''contains dosing details in manuscript'''" to "'''dosing details in manuscript have been reviewed'''") |
Warner-admin (talk | contribs) m (Text replacement - "#eeeeee" to "#82a4ff") |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 14: | Line 14: | ||
=Relapsed or refractory= | =Relapsed or refractory= | ||
==Alemtuzumab monotherapy {{#subobject:34416b|Regimen=1}}== | ==Alemtuzumab monotherapy {{#subobject:34416b|Regimen=1}}== | ||
| − | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#82a4ff"> |
===Regimen {{#subobject:#30ab57|Variant=1}}=== | ===Regimen {{#subobject:#30ab57|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 80%; text-align:center;" | {| class="wikitable sortable" style="width: 80%; text-align:center;" | ||
| Line 28: | Line 28: | ||
|- | |- | ||
|} | |} | ||
| − | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Immunosuppressive therapy==== | ====Immunosuppressive therapy==== | ||
*[[Alemtuzumab (Campath)]] as follows: | *[[Alemtuzumab (Campath)]] as follows: | ||
| Line 36: | Line 36: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | # Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. [https://doi.org/10.1046/j.1365-2141.2001.03039.x link to original article] '''dosing details in manuscript have been reviewed''' [https://pubmed.ncbi.nlm.nih.gov/11564082/ PubMed] | + | # Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. [https://doi.org/10.1046/j.1365-2141.2001.03039.x link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/11564082/ PubMed] |
==Sirolimus monotherapy {{#subobject:35516b|Regimen=1}}== | ==Sirolimus monotherapy {{#subobject:35516b|Regimen=1}}== | ||
| − | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#82a4ff"> |
===Regimen {{#subobject:#41ab57|Variant=1}}=== | ===Regimen {{#subobject:#41ab57|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 80%; text-align:center;" | {| class="wikitable sortable" style="width: 80%; text-align:center;" | ||
| Line 53: | Line 53: | ||
|- | |- | ||
|} | |} | ||
| − | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Immunosuppressive therapy==== | ====Immunosuppressive therapy==== | ||
*[[Sirolimus (Rapamune)]] 2 to 2.5 mg/m<sup>2</sup>/day PO | *[[Sirolimus (Rapamune)]] 2 to 2.5 mg/m<sup>2</sup>/day PO | ||
| Line 63: | Line 63: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | # Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. [https://doi.org/10.1182/blood-2015-07-657981 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705607/ link to PMC article] ''' | + | # Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. [https://doi.org/10.1182/blood-2015-07-657981 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705607/ link to PMC article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/26504182/ PubMed] [https://clinicaltrials.gov/study/NCT00392951 NCT00392951] |
[[Category:Autoimmune cytopenia regimens]] | [[Category:Autoimmune cytopenia regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
Latest revision as of 12:52, 31 July 2024
| Section editor | |
|---|---|
 |
Benjamin Tillman, MD Vanderbilt University Nashville, TN, USA |
This is an umbrella category that includes Felty's syndrome (autoimmune neutropenia), autoimmune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and Evan's syndrome (AIHA & ITP). Please see the respective page(s) for disease-specific therapies. This page includes regimens that were used more broadly.
- We have moved How I Treat articles to a dedicated page.
2 regimens on this page
2 variants on this page
|
Relapsed or refractory
Alemtuzumab monotherapy
Regimen
| Study | Dates of enrollment | Evidence | Efficacy |
|---|---|---|---|
| Willis et al. 2001 | 1995-11 to 2000-08 | Phase 2 | ORR: 71% |
Immunosuppressive therapy
- Alemtuzumab (Campath) as follows:
- Test dose: 1 mg IV over 60 minutes once
- Days 1 to 10: 10 mg IV over 4 hours once per day
10-day course
References
- Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. link to original article dosing details in manuscript have been reviewed by our editors PubMed
Sirolimus monotherapy
Regimen
| Study | Dates of enrollment | Evidence | Efficacy |
|---|---|---|---|
| Bride et al. 2015 | Not reported | Phase 2 | Durable CR observed in patients with ALPS |
Immunosuppressive therapy
- Sirolimus (Rapamune) 2 to 2.5 mg/m2/day PO
6-month course, extended for those with a favorable response
Dose and schedule modifications
- See manuscript for recommended dose adjustments
References
- Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. link to original article link to PMC article dosing details in abstract have been reviewed by our editors PubMed NCT00392951